Hege Elisabeth Giercksky Russnes
- Postdoc; MD
- +47 22 78 13 72
Publications 2024
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol (in press)
DOI 10.1002/1878-0261.13675, PubMed 38978352
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720
Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare
Acta Oncol, 63, 487-490
DOI 10.2340/1651-226X.2024.24954, PubMed 38910311
High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond
J Intern Med, 295 (6), 785-803
DOI 10.1111/joim.13785, PubMed 38698538
[Raising the quality of cancer treatment]
Tidsskr Nor Laegeforen, 144 (1)
DOI 10.4045/tidsskr.23.0740, PubMed 38258713
Desmoplastic non-infantile ganglioglioma mimicking diffuse leptomeningeal glioneuronal tumor: precision diagnostics and therapeutic implications
Acta Oncol, 63, 392-394
DOI 10.2340/1651-226X.2024.31720, PubMed 38779936
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
ESMO Open, 9 (6), 103475
DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
Acta Oncol, 63, 385-391
DOI 10.2340/1651-226X.2024.34791, PubMed 38779910
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
Ann Oncol (in press)
DOI 10.1016/j.annonc.2024.06.018, PubMed 39112111
Publications 2023
Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature
Curr Oncol, 30 (11), 10007-10018
DOI 10.3390/curroncol30110727, PubMed 37999147
A convolutional neural network STIFMap reveals associations between stromal stiffness and EMT in breast cancer
Nat Commun, 14 (1), 3561
DOI 10.1038/s41467-023-39085-1, PubMed 37322009
Publications 2022
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
JCO Precis Oncol, 6 (1), e2200015
DOI 10.1200/PO.22.00015, PubMed 35476549
Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models
Trends Pharmacol Sci, 43 (11), 973-985
DOI 10.1016/j.tips.2022.08.009, PubMed 36163057
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 225
DOI 10.1186/s12967-022-03432-5, PubMed 35568909
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 317
DOI 10.1186/s12967-022-03518-0, PubMed 35841045
Incidence of breast cancer subtypes in immigrant and non-immigrant women in Norway
Breast Cancer Res, 24 (1), 4
DOI 10.1186/s13058-021-01498-5, PubMed 35012613
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
Acta Oncol, 61 (8), 955-962
DOI 10.1080/0284186X.2022.2098053, PubMed 35943168
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Nat Med, 28 (12), 2573-2583
DOI 10.1038/s41591-022-02126-1, PubMed 36482103
A national precision cancer medicine implementation initiative for Norway
Nat Med, 28 (5), 885-887
DOI 10.1038/s41591-022-01777-4, PubMed 35513529
Publications 2021
Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
BMC Cancer, 21 (1), 1089
DOI 10.1186/s12885-021-08811-7, PubMed 34625038
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer
JCI Insight, 6 (11)
DOI 10.1172/jci.insight.147617, PubMed 33886505
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGFβ2
Nat Cancer, 2 (3), 327-339
DOI 10.1038/s43018-021-00179-8, PubMed 34993493
Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression
Mol Oncol, 16 (1), 88-103
DOI 10.1002/1878-0261.13047, PubMed 34165864
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int J Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768, PubMed 34449877
Publications 2020
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163
DNA copy number motifs are strong and independent predictors of survival in breast cancer
Commun Biol, 3 (1), 153
DOI 10.1038/s42003-020-0884-6, PubMed 32242091
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
Clinical trials in the era of precision cancer medicine - for the few or for the many?
Acta Oncol, 59 (7), 731-732
DOI 10.1080/0284186X.2020.1777582, PubMed 32579040
Publications 2019
Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 10 (1), 525
DOI 10.1038/s41467-019-08512-7, PubMed 30692535
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452
Microvessel density in breast cancer: the impact of field area on prognostic informativeness
J Clin Pathol, 72 (4), 304-310
DOI 10.1136/jclinpath-2018-205536, PubMed 30630872
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750
Publications 2018
Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 9 (1), 5397
DOI 10.1038/s41467-018-07842-2, PubMed 30559362
Number of Risky Lifestyle Behaviors and Breast Cancer Risk
JNCI Cancer Spectr, 2 (3), pky030
DOI 10.1093/jncics/pky030, PubMed 31360858
Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers
Ann Oncol, 29 (11), 2223-2231
DOI 10.1093/annonc/mdy404, PubMed 30252041
Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors
Mol Oncol, 12 (11), 1838-1855
DOI 10.1002/1878-0261.12375, PubMed 30133130
Publications 2017
AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
Mol Cancer Ther, 17 (1), 254-263
DOI 10.1158/1535-7163.MCT-16-0868, PubMed 29054988
Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 8 (1), 1221
DOI 10.1038/s41467-017-01355-0, PubMed 29089486
Alcohol, Physical Activity, Smoking, and Breast Cancer Subtypes in a Large, Nested Case-Control Study from the Norwegian Breast Cancer Screening Program
Cancer Epidemiol Biomarkers Prev, 26 (12), 1736-1744
DOI 10.1158/1055-9965.EPI-17-0611, PubMed 28877889
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
Cancer Discov, 7 (10), 1098-1115
DOI 10.1158/2159-8290.CD-17-0222, PubMed 28652380
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
Breast Cancer Res, 19 (1), 120
DOI 10.1186/s13058-017-0911-9, PubMed 29137653
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters
Am J Pathol, 187 (10), 2152-2162
DOI 10.1016/j.ajpath.2017.04.022, PubMed 28733194
Publications 2015
Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
Mol Oncol, 9 (4), 861-76
DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580
Publications 2014
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity
Cell Rep, 6 (3), 514-27
DOI 10.1016/j.celrep.2013.12.041, PubMed 24462293
Principles and methods of integrative genomic analyses in cancer
Nat Rev Cancer, 14 (5), 299-313
DOI 10.1038/nrc3721, PubMed 24759209
eEF2K--a new target in breast cancers with combined inactivation of p53 and PTEN
EMBO Mol Med, 6 (12), 1512-4
DOI 10.15252/emmm.201404683, PubMed 25471453
The multitude of molecular analyses in cancer: the opening of Pandora’s box
Genome Biol, 15 (9), 447
DOI 10.1186/s13059-014-0447-6, PubMed 25316146
Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors
Genes Chromosomes Cancer, 54 (4), 235-48
DOI 10.1002/gcc.22237, PubMed 25546585
Nuclear CSPP1 expression defined subtypes of basal-like breast cancer
Br J Cancer, 111 (2), 326-38
DOI 10.1038/bjc.2014.297, PubMed 24901235
GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images
Genome Biol, 15 (8), 442
DOI 10.1186/s13059-014-0442-y, PubMed 25168174
JARID1B is a luminal lineage-driving oncogene in breast cancer
Cancer Cell, 25 (6), 762-77
DOI 10.1016/j.ccr.2014.04.024, PubMed 24937458
Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status
BMC Cancer, 14, 211
DOI 10.1186/1471-2407-14-211, PubMed 24645668
Publications 2013
Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer
Cancer Res, 73 (21), 6424-34
DOI 10.1158/0008-5472.CAN-12-4573, PubMed 24030979
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer
Sci Transl Med, 5 (181), 181re1
DOI 10.1126/scitranslmed.3006112, PubMed 23596205
Publications 2012
Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
Acta Oncol, 52 (1), 91-101
DOI 10.3109/0284186X.2012.713508, PubMed 22934555
Publications 2011
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors
PLoS One, 6 (2), e16915
DOI 10.1371/journal.pone.0016915, PubMed 21364938
The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
Breast Cancer Res, 13 (3), R61
DOI 10.1186/bcr2898, PubMed 21672237
Paired distribution of molecular subtypes in bilateral breast carcinomas
Cancer Genet, 204 (2), 96-102
DOI 10.1016/j.cancergencyto.2010.09.012, PubMed 21504707
Insight into the heterogeneity of breast cancer through next-generation sequencing
J Clin Invest, 121 (10), 3810-8
DOI 10.1172/JCI57088, PubMed 21965338
Publications 2010
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors
Sci Signal, 3 (124), ra43
DOI 10.1126/scisignal.2000876, PubMed 20516477
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer (vol 1, pg 160, 2007)
Mol. Oncol., 4 (2), 169
DOI 10.1016/j.molonc.2010.01.003
Triple-negative breast cancer: present challenges and new perspectives
Mol Oncol, 4 (3), 209-29
DOI 10.1016/j.molonc.2010.04.006, PubMed 20537966
Molecular classification of breast carcinomas
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 979, 1 b. (flere pag.)
BIBSYS 101481047, ISBN 978-82-8072-585-1
Genomic architecture characterizes tumor progression paths and fate in breast cancer patients
Sci Transl Med, 2 (38), 38ra47
DOI 10.1126/scitranslmed.3000611, PubMed 20592421
Allele-specific copy number analysis of tumors
Proc Natl Acad Sci U S A, 107 (39), 16910-5
DOI 10.1073/pnas.1009843107, PubMed 20837533
Publications 2009
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161
Complex landscapes of somatic rearrangement in human breast cancer genomes
Nature, 462 (7276), 1005-10
DOI 10.1038/nature08645, PubMed 20033038
Publications 2008
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome
J Pathol, 214 (3), 357-67
DOI 10.1002/path.2278, PubMed 18044827
The estrogen receptor pathway in rhabdomyosarcoma: a role for estrogen receptor-beta in proliferation and response to the antiestrogen 4'OH-tamoxifen
Cancer Res, 68 (9), 3476-85
DOI 10.1158/0008-5472.CAN-07-3046, PubMed 18451176
Publications 2007
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer
Mol Oncol, 1 (2), 160-71
DOI 10.1016/j.molonc.2007.03.004, PubMed 19383292
Publications 2000
[Microdissection--an important tool in molecular biology]
Tidsskr Nor Laegeforen, 120 (5), 598-600
PubMed 10833921
Publications 1997
Comparison of genetic changes in frozen biopsies and microdissected archival material from the same colorectal liver metastases
Diagn Mol Pathol, 6 (6), 318-25
DOI 10.1097/00019606-199712000-00003, PubMed 9559291